Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 68-year-old man presents to the clinic to discuss management of newly diagnosed nonvalvular atrial fibrillation. His medical history includes hypertension, type 2 diabetes mellitus, and osteoarthritis. His current medications include lisinopril, metformin, and acetaminophen. His blood pressure is 134/82 mmHg, and his pulse is 88/min and irregularly irregular. The physician and patient agree to initiate apixaban therapy for stroke prophylaxis. Which of the following parameters must be evaluated prior to initiation and monitored periodically during this specific pharmacotherapy? (Select all that apply)

  1. Complete blood countCevap
  2. Serum creatinineCevap
  3. C
    Prothrombin time and international normalized ratio
  4. D
    Activated partial thromboplastin time
  5. E
    Non-contrast computed tomography of the head

Cevap

Complete blood count and serum creatinine
The correct choices are complete blood count and serum creatinine. Prior to initiating any systemic anticoagulant therapy, obtaining a baseline complete blood count is essential to document baseline hemoglobin and platelet levels. This helps in identifying underlying abnormalities and provides a reference point for monitoring potential occult bleeding during therapy. Furthermore, apixaban is partially cleared by the kidneys. Renal function, assessed via serum creatinine to estimate creatinine clearance, must be evaluated at baseline to ensure appropriate, safe dosing and to prevent drug accumulation. Renal function and complete blood count should subsequently be monitored periodically (at least annually, or more frequently depending on the patient's baseline renal impairment and clinical status).

Adım Adım Çözüm

1
Identify the chosen pharmacotherapy and its class.
Apixaban, which is a direct oral anticoagulant (DOAC) acting as a factor Xa inhibitor.
The drug class and mechanism of action dictate the specific baseline screening and ongoing monitoring requirements.
2
Determine the required baseline and ongoing laboratory testing for apixaban.
Baseline assessment of hemoglobin, platelets (via complete blood count), and renal function (via serum creatinine) is required.
Renal function must be evaluated to ensure safe dosing and prevent drug accumulation, while a complete blood count establishes a baseline to monitor for clinically significant bleeding or thrombocytopenia over time.
3
Evaluate the need for routine coagulation assays or advanced diagnostic imaging.
Neither routine coagulation assays nor head imaging are indicated in this scenario.
Unlike older anticoagulants, DOACs have highly predictable pharmacokinetics and do not require titration based on coagulation parameters. Furthermore, asymptomatic patients do not require neuroimaging prior to initiation.

Anahtar Kavram

Baseline and ongoing monitoring requirements for direct oral anticoagulants (DOACs)
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru